Anti-sclerostin antibodies such as romosozumab and blosozumab are the alternative drugs of mechanical strain-related stimulus that can overcome the mechanostat-related limitation of osteoporosis therapy (Figure 1) (5). This evidence concerns the gene SOST and osteoporosis.